Allison Bratzel
Stock Analyst at Piper Sandler
(4.36)
# 349
Out of 4,960 analysts
40
Total ratings
70%
Success rate
12.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $65 | $42.69 | +52.26% | 2 | Aug 22, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $77.28 | +44.93% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $5.67 | +288.01% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $11.71 | +181.81% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $29.78 | +286.17% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.19 | +88.09% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $4.32 | +501.85% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $660.00 | +9.85% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $17.92 | +22.77% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $41.50 | -44.58% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $35.49 | +18.34% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $11.92 | +84.56% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.58 | +153.16% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.93 | +237.27% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.39 | +355.58% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $85.04 | +17.59% | 2 | Feb 8, 2023 |
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $62 → $65
Current: $42.69
Upside: +52.26%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $77.28
Upside: +44.93%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $5.67
Upside: +288.01%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $11.71
Upside: +181.81%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $29.78
Upside: +286.17%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.19
Upside: +88.09%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $4.32
Upside: +501.85%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $660.00
Upside: +9.85%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $17.92
Upside: +22.77%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $41.50
Upside: -44.58%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $35.49
Upside: +18.34%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.92
Upside: +84.56%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.58
Upside: +153.16%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.93
Upside: +237.27%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.39
Upside: +355.58%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $85.04
Upside: +17.59%